|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM164324054 |
| 003 |
DE-627 |
| 005 |
20240704231811.0 |
| 007 |
tu |
| 008 |
231223s2006 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n1460.xml
|
| 035 |
|
|
|a (DE-627)NLM164324054
|
| 035 |
|
|
|a (NLM)16861040
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Oates, Jim C
|e verfasserin
|4 aut
|
| 245 |
1 |
4 |
|a The biology of nitric oxide and other reactive intermediates in systemic lupus erythematosus
|
| 264 |
|
1 |
|c 2006
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 05.01.2007
|
| 500 |
|
|
|a Date Revised 04.07.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Formation of reactive nitrogen and oxygen intermediates (RNI and ROI) is an essential part of the innate immune response. Markers of systemic RNI production are increased in the setting of systemic lupus erythematosus (SLE) activity. Several lines of evidence suggest mechanisms through which the activity of inducible nitric oxide synthase (iNOS) is pathogenic in SLE, including the ability of peroxynitrite (ONOO(-), a product of iNOS activity) to modify proteins, lipids, and DNA. These modifications can alter enzyme activity and may increase the immunogenicity of self antigens, leading to a break in immune tolerance. In humans, observational data suggest that overexpression of iNOS and increased production of ONOO(-) lead to glomerular and vascular pathology. Therapies designed to target iNOS activity or scavenge ROI and RNI are in development and may provide the means to reduce the pathogenic consequences of ROI and RNI in SLE
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
7 |
|a Reactive Nitrogen Species
|2 NLM
|
| 650 |
|
7 |
|a Reactive Oxygen Species
|2 NLM
|
| 650 |
|
7 |
|a Nitric Oxide
|2 NLM
|
| 650 |
|
7 |
|a 31C4KY9ESH
|2 NLM
|
| 650 |
|
7 |
|a Nitric Oxide Synthase
|2 NLM
|
| 650 |
|
7 |
|a EC 1.14.13.39
|2 NLM
|
| 700 |
1 |
|
|a Gilkeson, Gary S
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 121(2006), 3 vom: 09. Dez., Seite 243-50
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:121
|g year:2006
|g number:3
|g day:09
|g month:12
|g pages:243-50
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 121
|j 2006
|e 3
|b 09
|c 12
|h 243-50
|